SOLARA ACTIVE PHARMA SCIENCES LTD Q3 RESULTS
Long term Alpha generators: 8 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 27%
After a long period of time, recently an Indian pharma company announced its intention to takeover a reasonably sized European company. This is more than just a single development, it is reflecting a change in underlying operating matrix of the pharma industry which for the last many years has been going through a period of readjustment and is now coming out of it. Not many may know that an Indian hospital chain operates a hospital in Cayman Island. The Indian healthcare and pharma sector are two spaces which probably will grow at a much faster rate than other sectors. There are both macro and micro factors which will lead to higher growth. It is faster growth which leads to generation of alpha, which ideally is what investors are seeking when taking risk in equities
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Q1 results today: ITC, Tata Motors among 88 companies will announce earnings on Thursday
Earnings season commenced with 88 companies announcing results. Key highlights included ITC, Sun Pharma, Tata Motors, Adani Enterprises, and Zomato reporting. ITC and Dabur anticipated revenue growth from cigarettes, hotels, and FMCG segments. Tata Motors projected strong profit growth. Zomato maintained robust performance from prior quarters, offering promising outlooks.
Q1 results this week: ITC, SBI, TaMo, Zomato among 130 firms to announce earnings
This week, several prominent companies released their June quarter financial results. Firms like ITC, SBI, Adani Ports, Tata Motors, and M&M showcased their reports between July 29th and August 3rd. The updates offered a glimpse into their quarterly performance, engaging the attention of investors and stakeholders.
Tech Mahindra Q1 Results: Profit jumps 23% YoY to Rs 851 crore, misses estimates
Tech Mahindra Q1 Results: Tech Mahindra reported a 23% year-on-year growth in consolidated net profit to Rs 851 crore for the June quarter, slightly below the expected Rs 892 crore. Revenue from operations declined 1% YoY to Rs 13,005 crore. Sequentially, profit after tax rose by 28% and revenue increased by 1%.
Q1 results, FII action among 10 factors to impact D-Street mood this week
Nifty gained 1.2%, driven by IT, energy, and pharma stocks. U.S. labor data, TCS earnings, Rupee vs. Dollar, Bank Nifty, oil prices, FIIs, IPO action, and dividends will influence markets next week. Bulls maintain strength with positive sentiment and broader market participation, expecting some consolidation.
- Go To Page 1
Time to buy pharma? 3 stocks Forum Parekh is betting on
Zydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life will tend to report some 25% EBITDA margin. Therefore, Sharekhan By BNP Paribas has a buy call on Zydus Life with a price target of almost Rs 1200, says Foram Parekh
Stocks with tailwinds called advantage India: 5 largecap stocks from 3 different sectors with an upside potential of upto 36 %
In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sentiment was very bullish. The only difference between then and now is that we have election results which are coming up. Surely a confirmation on 4th June that continuity in the policy making is a big factor. But there is another thing which long term investors need to look at before investing. Whether the company or the sector has an advantage due to India as a country. A well known example, which has been present for decades is that of the IT industry. India as a country is a factory of software engineers, and that is our strength. So when investing for the long term, look at sectors where we have some strong tailwinds due to our human capital.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profit
Strides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. Pre-tax profit was Rs 29.6 crore.
Strides Pharma Q4 Results: Firm posts net profit of Rs 10 crore vs loss YoY
Strides Pharma Science Ltd reported a net profit of Rs 10.44 crore in Q4 ended March 2024. The company announced Arun Kumar as Executive Chairperson. Consolidated total income was Rs 1,070.49 crore with expenses at Rs 984.21 crore. A final dividend of Rs 2.50 per equity share was recommended. FY24 revenue grew driven by US and regulated markets.
How to trade Maruti, RIL and 4 other stocks ahead of Q4 earnings
India VIX surged 17%, prompting trading strategies for Maruti, RIL, Tata Consumer Products, Axis Bank, Bajaj Finance, and HUL. Technical analysis indicated positive market movements with RSI and stochastic indicators. Watch for Iran-Israel developments and India VIX levels at 15.
Only 39 smallcap stocks rise in double-digits as geopolitical concerns, lofty valuations weigh
Indian markets faced pressure from Middle East concerns, impacting smallcap stocks' returns. Top gainers included Moschip Technologies, Solara Active Pharma, and Dhani Services.
Q3 Results: How did 5 key sectors perform during the quarter?
Insights from management commentaries provide indicators of the Indian economy's health in Oct-Dec quarter. IT sector revenue growth remains muted. Pharma sector sees promising PAT growth. Banking sector experiences robust credit growth. Auto sector witnesses deceleration in volume growth. FMCG sector faces slow sales growth.
Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic sales
Total revenue from operations declined to Rs 2,507 crore as compared with Rs 3,100 crore in the year-ago period, Glenmark Pharma said in a statement.
Alembic Pharma posts Rs 180 crore net profit in Q3FY24
Drug maker Alembic Pharma on Monday reported Rs 180 crore net profit in Q3FY24, which is a 48% year-on-year (YoY) increase compared to the corresponding period of the previous year led by India and US sales growth.
Alembic Pharma Q3 Results: Profit beats Street view on strong domestic, US sales
India's Alembic Pharmaceuticals reported a bigger-than-expected third-quarter profit on Monday, driven by higher sales in the domestic and U.S. markets.
Q3 results this week: ITC, Adani Ports, Bajaj Finance, IndiGo, SBI, Tata Motors and others
ITC, Bajaj Finance, NTPC, Adani Green Energy, Bharat Electronics, Punjab National Bank, GAIL, Bharat Petroleum, Corporation, Vodafone Idea, Marico, Petronet LNG, Nippon Life India Asset Management, Tata Investment Corporation, Piramal Enterprises, R R Kabel, Aditya Birla Sun Life AMC, Maharashtra Seamless, Nuvoco Vistas Corporation, Godfrey Phillips India, among others will report their December quarter numbers on Jan 29
Laurus Labs shares crash 10% after missing Q3 estimates
In Q3, the company's revenue dropped 23% year-on-year (YoY) at Rs 1,195 crore while profit also dropped 89% YoY to Rs 23 crore.
Glenmark Life Sciences Q3 Results: Net profit rises 13% YoY to Rs 119 crore
Glenmark Life Sciences on Tuesday said its net profit increased 13 per cent to Rs 119 crore for the third quarter ended December 2023. The company had reported a net profit of Rs 105 crore in October-December period of the last fiscal.
Granules India Q3 Results: Paracetamol maker posts marginal rise in profit
Drug maker Granules India reported a marginal rise in third-quarter profit on Tuesday, helped by easing raw material costs.
Axis Bank, Bajaj Auto Q3 earnings among 10 factors to drive D-Street in holiday-shortened week
"Nifty concluded the week at 21,571.80, marking a decline of 323 points from 21,894 levels, on a weekly basis. Pharma, realty, and metal sectors faced selling pressure. Despite persstent attempts to breach crucial resistance, each of them resulted in a sell-off,” Om Mehra, Technical Analyst, at SAMCO Securities said.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Aurobindo Pharma Q2 Results: Net profit soars 84% to Rs 752 crore on strong overseas demand
Aurobindo Pharma on Thursday reported 84% year-on-year (YoY) rise in net profit to Rs 752 crore in the second quarter ended September 2023, led by strong sales from the US market.
Poor EHS compliance a latent risk for pharma, chemical companies
"The general level of awareness and compliance related to EHS (Environment Health & Safety) norms in case of manufacturing companies requires drastic improvement and urgent attention" said Nagaraj Krishnan, managing director, Aparajitha Corporate Services, a tech firm providing compliance solutions to over 2000 companies in India.
Glenmark Life Sciences Q2 Results: Firm posts profit rise on API boost
However, a nearly 18% rise in expenses ate into the company's core profit margin, which contracted to 29% from 30.2% a year earlier.
Q2 results: These 17 companies are likely to report loss. What should investors do?
Restaurant Brands Asia, which runs Burger King India, is seen reporting a quarterly loss of Rs 15.7 crore. While Kotak has a 'reduce' rating on the stock, Motilal has given a buy rating.
On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%
As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.
3 years since COVID: 35 stocks trading below March 2020 levels; do you own any?
While domestic equities have rebounded sharply from the levels they were trading before the nation went into a lockdown in March 2020, there are several stocks which have failed to sustain the recovery and are in fact, trading below the Covid levels.
Load More
